![]() |
Name |
Cyclo(L-leucyl-L-phenylalanyl)
|
Molecular Formula | C15H20N2O2 | |
IUPAC Name* |
(3S,6S)-3-benzyl-6-(2-methylpropyl)piperazine-2,5-dione
|
|
SMILES |
CC(C)C[C@H]1C(=O)N[C@H](C(=O)N1)CC2=CC=CC=C2
|
|
InChI |
InChI=1S/C15H20N2O2/c1-10(2)8-12-14(18)17-13(15(19)16-12)9-11-6-4-3-5-7-11/h3-7,10,12-13H,8-9H2,1-2H3,(H,16,19)(H,17,18)/t12-,13-/m0/s1
|
|
InChIKey |
QPDMOMIYLJMOQJ-STQMWFEESA-N
|
|
Synonyms |
7280-77-5; CYCLO(-LEU-PHE); Cyclo(Leu-Phe); cyclo(L-Phe-L-Leu); Cyclo(L-leucyl-L-phenylalanyl); Cyclo(Phe-Leu); cyclo(L-phenylalanyl-L-leucyl); L-Phenylalanyl-L-leucine diketopiperazine; cyclo(L-Leu-L-Phe); (3S,6S)-3-benzyl-6-(2-methylpropyl)piperazine-2,5-dione; CHEBI:71608; 2,5-Piperazinedione, 3-(2-methylpropyl)-6-(phenylmethyl)-, (3S,6S)-; (3S,6S)-3-benzyl-6-isobutylpiperazine-2,5-dione; (3S,6S)-3-(2-Methylpropyl)-6-(phenylmethyl)-2,5-piperazinedione; Cyclo(-L-Leu-L-Phe); Cyclo(leucyl-phenylalanyl); Cyclo(L-Leu-L-Phe-); cyclo(-leu-phe), AldrichCPR; CHEMBL189999; SCHEMBL2864427; 2,5-Piperazinedione, 3-benzyl-6-isobutyl-, (3S,6S)-; Cyclo-(l-leucyl-l-phenylalanyl); DTXSID20993602; ZINC4026203; MFCD00672388; 2,5-Piperazinedione, 3-(2-methylpropyl)-6-(phenylmethyl)-, (3S-cis)-; AKOS027250806; 3-Benzyl-6-isobutyl-2,5-piperazinedione #; C20519; Q27139751; 3-Benzyl-6-(2-methylpropyl)-3,6-dihydropyrazine-2,5-diol; cFL
|
|
CAS | 7280-77-5 | |
PubChem CID | 7076347 | |
ChEMBL ID | CHEMBL189999 |
Chemical Classification: |
|
|
---|
Molecular Weight: | 260.33 | ALogp: | 2.4 |
HBD: | 2 | HBA: | 2 |
Rotatable Bonds: | 4 | Lipinski's rule of five: | Accepted |
Polar Surface Area: | 58.2 | Aromatic Rings: | 2 |
Heavy Atoms: | 19 | QED Weighted: | 0.866 |
Caco-2 Permeability: | -4.597 | MDCK Permeability: | 0.00011894 |
Pgp-inhibitor: | 0.002 | Pgp-substrate: | 0.005 |
Human Intestinal Absorption (HIA): | 0.007 | 20% Bioavailability (F20%): | 0.006 |
30% Bioavailability (F30%): | 0.002 |
Blood-Brain-Barrier Penetration (BBB): | 0.74 | Plasma Protein Binding (PPB): | 67.92% |
Volume Distribution (VD): | 0.557 | Fu: | 24.29% |
CYP1A2-inhibitor: | 0.088 | CYP1A2-substrate: | 0.091 |
CYP2C19-inhibitor: | 0.469 | CYP2C19-substrate: | 0.287 |
CYP2C9-inhibitor: | 0.401 | CYP2C9-substrate: | 0.804 |
CYP2D6-inhibitor: | 0.018 | CYP2D6-substrate: | 0.306 |
CYP3A4-inhibitor: | 0.506 | CYP3A4-substrate: | 0.257 |
Clearance (CL): | 4.403 | Half-life (T1/2): | 0.618 |
hERG Blockers: | 0.03 | Human Hepatotoxicity (H-HT): | 0.462 |
Drug-inuced Liver Injury (DILI): | 0.124 | AMES Toxicity: | 0.251 |
Rat Oral Acute Toxicity: | 0.666 | Maximum Recommended Daily Dose: | 0.088 |
Skin Sensitization: | 0.085 | Carcinogencity: | 0.091 |
Eye Corrosion: | 0.003 | Eye Irritation: | 0.016 |
Respiratory Toxicity: | 0.038 |